ImmuCell Corporation — Q3 2023 Form 10-Q
Business context and period. Unaudited results for the three and nine months ended September 30, 2023, compared with the same 2022 periods. ImmuCell develops and sells animal-health products; First Defense, for preventing scours in calves, generated 99% of nine-month sales. Re-Tain, a treatment for subclinical mastitis, remained in development and requires FDA approval before U.S. sales.
Key financial metrics
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Product sales | $5.40 million | $4.80 million | $12.38 million | $14.66 million |
| Gross margin | $1.27 million (23%) | $1.85 million (38%) | $2.61 million (21%) | $6.66 million (45%) |
| Operating loss | $1.18 million | $617,000 | $4.74 million | $665,000 |
| Net loss; loss per share | $940,000; $0.12 | $655,000; $0.08 | $4.63 million; $0.60 | $826,000; $0.11 |
- Cash flow and liquidity: Nine-month operating cash outflow was $3.95 million, investing cash outflow $1.92 million, and financing cash inflow $2.07 million. Cash fell to $1.99 million from $5.79 million at year-end 2022. Net working capital was $8.63 million.
- Debt: Total debt obligations were $12.32 million, versus $10.23 million at year-end 2022. The company obtained $3 million of new fixed-rate loans in Q3, bearing 7% and 8% interest. The reported blended rate on outstanding debt was 4.52%. Debt is substantially secured by company assets.
- Balance sheet: Inventory was $7.39 million, up from $6.04 million at year-end; stockholders’ equity was $26.01 million, down from $30.38 million. The company reported $4.37 million in operating lease liabilities.
Material changes and drivers
- Q3 sales rose 13% year over year, but nine-month sales fell 16%. Management attributed the year-to-date decline mainly to production interruptions and insufficient supply, rather than lower demand.
- Nine-month gross margin declined by $4.05 million. Lower production reduced sales and fixed-cost absorption; costs of goods sold included $461,000 of scrapped inventory write-offs. Gross margin also reflected higher costs and variable production yields.
- Q3 other income included a $365,000 insurance recovery related to contamination losses and an equipment malfunction. This benefit partly offset the operating loss.
- Cash used in operations rose substantially from the prior-year period, primarily as the net loss increased. Capital expenditures were $1.81 million for the nine months.
Outlook, risks and unusual items
- Production and backlog: Management said quality-control results indicated contamination issues were largely behind the company and that it was resuming production. It reported an approximately $8.9 million backlog at September 30 and approximately $8.8 million at October 27, 2023, but cautioned that orders may be old, duplicative, or cancelled. A September contamination event affected two work-in-process lots, with about $155,000 in scrap costs; the resulting pause was expected to reduce Q4 production by approximately $750,000 in sales value.
- Capacity and sales goals: Management estimated annual First Defense capacity of approximately $30 million in late Q4 2023 and into 2024, and stated a goal of producing at least $6 million per quarter. It aims to exceed approximately $19 million in annual product sales as soon as possible. These are targets, not assured results; capacity depends on yields, product mix, pricing, and execution.
- Re-Tain regulatory and commercial outlook: Four of five FDA technical sections had been completed. In late October, the FDA said it was not reviewing the August CMC submission because the filing identified Norbrook as drug-product manufacturer when FDA expected the company to identify its own services. ImmuCell refiled in November and was discussing whether the review period could run from the August submission date. Approval timing therefore remains uncertain. Management’s controlled-launch estimates are about $1 million in first-year sales and $2 million in the second year after launch; both depend on approval and execution.
- Investment plans: Due to reduced gross margin, the company deferred much of its First Defense expansion and approximately $1.7 million of planned Re-Tain in-house formulation and filling investment. Norbrook was expected to manufacture Re-Tain drug product for the first two years of projected commercial sales; longer-term supply arrangements remain a risk.
- Debt covenant and runway: The bank waived the 2023 debt-service coverage covenant. A 1.35 minimum ratio applies to the twelve-month periods ending June 30, September 30, and December 31, 2024, and annually thereafter. Management believed cash and anticipated product gross margin would fund planned working capital, capital expenditures, and operations for at least 12 months from filing; continued losses and debt service could pressure liquidity.
- Concentration and other risks: Two customers accounted for 79% of nine-month sales and 81% of receivables. The company cited production contamination or equipment failure, supply-chain and inflation pressures, customer losses during shortages, regulatory delays, and dependence on First Defense as key risks. In Q2 it identified a material weakness involving capitalization of depreciation in inventory; it said the weakness was remediated in Q3 and controls were effective at September 30.
Important facts for investors to verify
- Whether production quality and output recover sustainably, and whether backlog converts to shipped sales without further customer attrition.
- The status and FDA review timing of the refiled Re-Tain CMC submission, facility inspection, and approval requirements.
- Cash burn, available liquidity, capital spending, debt repayments, and compliance with the 2024 debt-service coverage tests.
- Whether gross margins recover from the 21% nine-month level and whether contamination-related costs or write-offs recur.
- Customer and receivables concentration, and the company’s arrangements for Re-Tain contract manufacturing and future supply.